Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | CDC25A | P30304 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756157 | 0.85 | SIGMAR1 (0.46) | CNR2ALDH1A1HTTL3MBTL1 | |
| SCHEMBL5755381 | 0.71 | LMNA (0.36) | CNR2ALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL5753558 | 0.70 | CNR2 (0.43) | CNR2CNR1ALDH1A1HTTLMNA | |
| SCHEMBL5756372 | 0.70 | CNR2 (0.42) | CNR2CNR1HTTLMNASMN1; SMN2 | |
| Hexane SCHEMBL27460259 | 0.69 | HSD17B10 (0.56) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5754142 | 0.69 | MEN1 (0.42) | CNR2CNR1ALDH1A1HTTLMNA | |
| SCHEMBL5756915 | 0.68 | CNR2 (0.43) | CNR2CNR1ALDH1A1HTTLMNA | |
| SCHEMBL5754810 | 0.68 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL8090169 | 0.68 | POLB (0.58) | ALDH1A1L3MBTL1CES1CDC25ALMNA | |
| Pentane SCHEMBL27733467 | 0.66 | HSD17B10 (0.56) | ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140828-B1 | 3-AZABICYCLO¬3.1.0|HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LTD (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-7049444-B2 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. (US) | 2003-01-16 | — | — | US | disclosed |
| US-6313312-B1 | OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| EP-1140828-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | CNR2 100/4885CNR1 31/4885ALDH1A1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.